Show simple item record

dc.creatorPandey, Satish Chandra
dc.creatorPande, Veni
dc.creatorSati, Diksha
dc.creatorUpreti, Shobha
dc.creatorSamant, Mukesh
dc.date.accessioned2020-08-05T14:19:35Z
dc.date.available2020-08-05T14:19:35Z
dc.date.created2020
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://doi.org/10.1016/j.lfs.2020.117956spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11631
dc.description.abstractThe 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China. Now COVID-19 has been spread all over the world and declared epidemics by WHO. It has caused a Public Health Emergency of International Concern. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Due to the rapid increase of SARS-CoV-2 infections and unavailability of antiviral therapeutic agents, developing an effective SAR-CoV-2 vaccine is urgently required. SARS-CoV-2 which is genetically similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERSCoV) is an enveloped, single and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins which are very similar to SARS-CoV and MERS-CoV proteins. In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates could be used as a potential tool for the development of a safe and effective vaccine against SARS-CoV-2.spa
dc.format.extent9 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherScience Directeng
dc.publisherLife Sciencesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCorona virusspa
dc.subjectEpidemicsspa
dc.subjectSARS-CoV-2spa
dc.subjectMERS-CoVspa
dc.subjectVaccinespa
dc.titleVaccination strategies to combat novel corona virus SARS-CoV-2spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.117956spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record